DD284875A5 - Verfahren zur herstellung von 1-[(diarylmethoxy)-alkyl]-pyrrolidinen und -piperidinen - Google Patents
Verfahren zur herstellung von 1-[(diarylmethoxy)-alkyl]-pyrrolidinen und -piperidinen Download PDFInfo
- Publication number
- DD284875A5 DD284875A5 DD89332899A DD33289989A DD284875A5 DD 284875 A5 DD284875 A5 DD 284875A5 DD 89332899 A DD89332899 A DD 89332899A DD 33289989 A DD33289989 A DD 33289989A DD 284875 A5 DD284875 A5 DD 284875A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- pyrrolidine
- methoxyphenyl
- diphenylmethoxy
- solution
- ethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract 8
- 150000003053 piperidines Chemical class 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- -1 aryl pyrrolidine Chemical compound 0.000 claims description 16
- MDZWFRVPKYMLPL-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CNCC2)=C1 MDZWFRVPKYMLPL-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- XONCWXYGZWWPFZ-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CN(CCOC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 XONCWXYGZWWPFZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- ZIOFREVANSHGDE-UHFFFAOYSA-N 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CN(CCOC(C=3C=CC(F)=CC=3)C=3C=CC(F)=CC=3)CC2)=C1 ZIOFREVANSHGDE-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- CASLHHLEQGBDKK-UHFFFAOYSA-N 1-[1-bromoethoxy-(4-fluorophenyl)methyl]-4-fluorobenzene Chemical compound C=1C=C(F)C=CC=1C(OC(Br)C)C1=CC=C(F)C=C1 CASLHHLEQGBDKK-UHFFFAOYSA-N 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003235 pyrrolidines Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
- 239000000243 solution Substances 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- 239000003480 eluent Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- MUKSLGKYFRLGOB-UHFFFAOYSA-N 1-[2-bromoethoxy-(4-fluorophenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(OCCBr)C1=CC=C(F)C=C1 MUKSLGKYFRLGOB-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 235000006408 oxalic acid Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000012429 reaction media Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- PXMDLNFRUVGKCU-UHFFFAOYSA-N 2-benzhydryloxyacetyl chloride Chemical compound C=1C=CC=CC=1C(OCC(=O)Cl)C1=CC=CC=C1 PXMDLNFRUVGKCU-UHFFFAOYSA-N 0.000 description 5
- HYARBELXZXURQQ-UHFFFAOYSA-N [2-bromoethoxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(OCCBr)C1=CC=CC=C1 HYARBELXZXURQQ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XTSOHPFZIJWIJK-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-3-(3-methoxyphenyl)piperidine;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(C2CN(CCOC(C=3C=CC=CC=3)C=3C=CC=CC=3)CCC2)=C1 XTSOHPFZIJWIJK-UHFFFAOYSA-N 0.000 description 3
- ZGNWABHCIIYZFN-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-3-phenylpiperidine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(C1)CCCC1C1=CC=CC=C1 ZGNWABHCIIYZFN-UHFFFAOYSA-N 0.000 description 3
- RWSALXYPUGXDLJ-UHFFFAOYSA-N 1-[3-bromopropoxy-(4-fluorophenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(OCCCBr)C1=CC=C(F)C=C1 RWSALXYPUGXDLJ-UHFFFAOYSA-N 0.000 description 3
- ISIDMZGZFSGSBH-UHFFFAOYSA-N 2-benzhydryloxy-1-(3-phenylpiperidin-1-yl)ethanone Chemical compound C1CCC(C=2C=CC=CC=2)CN1C(=O)COC(C=1C=CC=CC=1)C1=CC=CC=C1 ISIDMZGZFSGSBH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BJWBUBPPFLVWPX-UHFFFAOYSA-N [2-bromopropoxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(OCC(Br)C)C1=CC=CC=C1 BJWBUBPPFLVWPX-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- OQROAIRCEOBYJA-UHFFFAOYSA-N bromodiphenylmethane Chemical compound C=1C=CC=CC=1C(Br)C1=CC=CC=C1 OQROAIRCEOBYJA-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 3
- 229960000326 flunarizine Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- HGUFAMQASNRTCP-UHFFFAOYSA-N 1-(1-benzhydryloxypropan-2-yl)-3-(3-methoxyphenyl)pyrrolidine;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(C2CN(CC2)C(C)COC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 HGUFAMQASNRTCP-UHFFFAOYSA-N 0.000 description 2
- PJUQSICNDGZQIR-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-3-(3-methoxyphenyl)pyrrolidine;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(C2CN(CCOC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 PJUQSICNDGZQIR-UHFFFAOYSA-N 0.000 description 2
- VEBTZBKGJSKRBA-UHFFFAOYSA-N 1-(3-benzhydryloxypropyl)-3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CN(CCCOC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 VEBTZBKGJSKRBA-UHFFFAOYSA-N 0.000 description 2
- RFKYBVKHJCQTRJ-WLHGVMLRSA-N 1-[3-[bis(4-fluorophenyl)methoxy]propyl]-3-(3-methoxyphenyl)pyrrolidine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.COC1=CC=CC(C2CN(CCCOC(C=3C=CC(F)=CC=3)C=3C=CC(F)=CC=3)CC2)=C1 RFKYBVKHJCQTRJ-WLHGVMLRSA-N 0.000 description 2
- HXDAZUSPEXGQSS-UHFFFAOYSA-N 1-[bromo-(4-fluorophenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(Br)C1=CC=C(F)C=C1 HXDAZUSPEXGQSS-UHFFFAOYSA-N 0.000 description 2
- KTJJUKVTVSPXMV-UHFFFAOYSA-N 2-benzhydryloxy-1-(4-phenylpiperidin-1-yl)ethanone Chemical compound C1CC(C=2C=CC=CC=2)CCN1C(=O)COC(C=1C=CC=CC=1)C1=CC=CC=C1 KTJJUKVTVSPXMV-UHFFFAOYSA-N 0.000 description 2
- KWGQOJWITMQEOT-UHFFFAOYSA-N 2-benzhydryloxyacetic acid Chemical compound C=1C=CC=CC=1C(OCC(=O)O)C1=CC=CC=C1 KWGQOJWITMQEOT-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- KPLSJXSTLNRLAF-UHFFFAOYSA-N 3-(3-propan-2-yloxyphenyl)pyrrolidine Chemical compound CC(C)OC1=CC=CC(C2CNCC2)=C1 KPLSJXSTLNRLAF-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- GFZQIBGSJFUBPU-UHFFFAOYSA-N [3-bromopropoxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(OCCCBr)C1=CC=CC=C1 GFZQIBGSJFUBPU-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- IVRZVPSCZNKBDM-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-2-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2N(CCC2)CCOC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 IVRZVPSCZNKBDM-UHFFFAOYSA-N 0.000 description 1
- PHWZDIJXNWOTLB-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-2-phenylpyrrolidine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN1CCCC1C1=CC=CC=C1 PHWZDIJXNWOTLB-UHFFFAOYSA-N 0.000 description 1
- SPIYCHGELGRFNC-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-2-phenylpyrrolidine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN1CCCC1C1=CC=CC=C1 SPIYCHGELGRFNC-UHFFFAOYSA-N 0.000 description 1
- FTNQRMDSLZCGQD-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-3-(3,4-dimethoxyphenyl)pyrrolidine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=C(OC)C(OC)=CC=C1C1CN(CCOC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 FTNQRMDSLZCGQD-UHFFFAOYSA-N 0.000 description 1
- XJRVEEQJMUPJDI-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)-4-phenylpiperidine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(CC1)CCC1C1=CC=CC=C1 XJRVEEQJMUPJDI-UHFFFAOYSA-N 0.000 description 1
- RJPYOKIVJCMREB-UHFFFAOYSA-N 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-2-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2N(CCC2)CCOC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=C1 RJPYOKIVJCMREB-UHFFFAOYSA-N 0.000 description 1
- YDKUYAICYRWFMP-WLHGVMLRSA-N 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-2-(3-methoxyphenyl)pyrrolidine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.COC1=CC=CC(C2N(CCC2)CCOC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=C1 YDKUYAICYRWFMP-WLHGVMLRSA-N 0.000 description 1
- GCUHGOIVROQJRK-UHFFFAOYSA-N 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-3-(3-propan-2-yloxyphenyl)pyrrolidine Chemical compound CC(C)OC1=CC=CC(C2CN(CCOC(C=3C=CC(F)=CC=3)C=3C=CC(F)=CC=3)CC2)=C1 GCUHGOIVROQJRK-UHFFFAOYSA-N 0.000 description 1
- BFHUXDKUSMARCA-UHFFFAOYSA-N 1-[3-[bis(4-fluorophenyl)methoxy]propyl]-3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CN(CCCOC(C=3C=CC(F)=CC=3)C=3C=CC(F)=CC=3)CC2)=C1 BFHUXDKUSMARCA-UHFFFAOYSA-N 0.000 description 1
- QGKFYRMABWIOIW-UHFFFAOYSA-N 2-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2NCCC2)=C1 QGKFYRMABWIOIW-UHFFFAOYSA-N 0.000 description 1
- CHINZSUVUBYWGD-UHFFFAOYSA-N 2-benzhydryloxy-1-[3-(3-methoxyphenyl)piperidin-1-yl]ethanone Chemical compound C1(=CC=CC=C1)C(OCC(=O)N1CC(CCC1)C1=CC(=CC=C1)OC)C1=CC=CC=C1 CHINZSUVUBYWGD-UHFFFAOYSA-N 0.000 description 1
- DBTWOTKWIVISQR-UHFFFAOYSA-N 2-bromopropan-1-ol Chemical compound CC(Br)CO DBTWOTKWIVISQR-UHFFFAOYSA-N 0.000 description 1
- JUTDHSGANMHVIC-UHFFFAOYSA-N 2-phenylpyrrolidine Chemical compound C1CCNC1C1=CC=CC=C1 JUTDHSGANMHVIC-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- LDHSRVLRYZPWRD-UHFFFAOYSA-N 3-(2-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC=C1C1CNCC1 LDHSRVLRYZPWRD-UHFFFAOYSA-N 0.000 description 1
- HQHZEQCBQADPSO-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)pyrrolidine Chemical compound C1=C(OC)C(OC)=CC=C1C1CNCC1 HQHZEQCBQADPSO-UHFFFAOYSA-N 0.000 description 1
- HAJKRJTVGSUQQF-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)pyrrolidine Chemical compound COC1=CC(OC)=CC(C2CNCC2)=C1 HAJKRJTVGSUQQF-UHFFFAOYSA-N 0.000 description 1
- LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NZYBILDYPCVNMU-UHFFFAOYSA-N 3-phenylpiperidine Chemical compound C1CCNCC1C1=CC=CC=C1 NZYBILDYPCVNMU-UHFFFAOYSA-N 0.000 description 1
- PRRFFTYUBPGHLE-UHFFFAOYSA-N 3-phenylpyrrolidine Chemical compound C1NCCC1C1=CC=CC=C1 PRRFFTYUBPGHLE-UHFFFAOYSA-N 0.000 description 1
- NOBKCEXLDDGYID-UHFFFAOYSA-N 3-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=CC(C=O)=C1 NOBKCEXLDDGYID-UHFFFAOYSA-N 0.000 description 1
- NONQCMNVMIGQEE-UHFFFAOYSA-N 4-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CCNCC2)=C1 NONQCMNVMIGQEE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- UASJZNUESCZOTH-UHFFFAOYSA-N C(C(=O)O)(=O)O.C1(=CC=CC=C1)C(OCCN1CCC(CC1)C1=CC(=CC=C1)OC)C1=CC=CC=C1 Chemical compound C(C(=O)O)(=O)O.C1(=CC=CC=C1)C(OCCN1CCC(CC1)C1=CC(=CC=C1)OC)C1=CC=CC=C1 UASJZNUESCZOTH-UHFFFAOYSA-N 0.000 description 1
- IPWWZOITFDOSTP-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.FC1=CC=C(C=C1)C(OCCN1CC(CC1)C1=CC(=CC=C1)OC)C1=CC=C(C=C1)F Chemical compound C(C=CC(=O)O)(=O)O.FC1=CC=C(C=C1)C(OCCN1CC(CC1)C1=CC(=CC=C1)OC)C1=CC=C(C=C1)F IPWWZOITFDOSTP-UHFFFAOYSA-N 0.000 description 1
- XSALHFHTQKQTQX-BTJKTKAUSA-N C(\C=C/C(=O)O)(=O)O.C1(=CC=CC=C1)C(OCCN1CC(CC1)C1=C(C=CC=C1)OC)C1=CC=CC=C1 Chemical compound C(\C=C/C(=O)O)(=O)O.C1(=CC=CC=C1)C(OCCN1CC(CC1)C1=C(C=CC=C1)OC)C1=CC=CC=C1 XSALHFHTQKQTQX-BTJKTKAUSA-N 0.000 description 1
- PTOFALCVGBUWTP-UHFFFAOYSA-N C1(=CC=CC=C1)C(OCCN1CC(CC1)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)C(OCCN1CC(CC1)C1=CC=CC=C1)C1=CC=CC=C1 PTOFALCVGBUWTP-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- BYQADQLDVPAGSR-UHFFFAOYSA-N toluene;hydrobromide Chemical compound Br.CC1=CC=CC=C1 BYQADQLDVPAGSR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- H—ELECTRICITY
- H03—ELECTRONIC CIRCUITRY
- H03H—IMPEDANCE NETWORKS, e.g. RESONANT CIRCUITS; RESONATORS
- H03H7/00—Multiple-port networks comprising only passive electrical elements as network components
- H03H7/01—Frequency selective two-port networks
- H03H7/09—Filters comprising mutual inductance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8812430A FR2636946B1 (fr) | 1988-09-23 | 1988-09-23 | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD284875A5 true DD284875A5 (de) | 1990-11-28 |
Family
ID=9370298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD89332899A DD284875A5 (de) | 1988-09-23 | 1989-09-22 | Verfahren zur herstellung von 1-[(diarylmethoxy)-alkyl]-pyrrolidinen und -piperidinen |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4957927A (cs) |
| EP (1) | EP0360685B1 (cs) |
| JP (1) | JPH02121964A (cs) |
| AR (1) | AR246255A1 (cs) |
| AT (1) | ATE101132T1 (cs) |
| AU (1) | AU617530B2 (cs) |
| CA (1) | CA1327364C (cs) |
| CZ (1) | CZ279282B6 (cs) |
| DD (1) | DD284875A5 (cs) |
| DE (1) | DE68912860T2 (cs) |
| DK (1) | DK468389A (cs) |
| ES (1) | ES2062071T3 (cs) |
| FR (1) | FR2636946B1 (cs) |
| HU (1) | HU208422B (cs) |
| IE (1) | IE63648B1 (cs) |
| IL (1) | IL91689A0 (cs) |
| MA (1) | MA21631A1 (cs) |
| NO (1) | NO893764L (cs) |
| NZ (1) | NZ230744A (cs) |
| OA (1) | OA09135A (cs) |
| PT (1) | PT91783B (cs) |
| SU (1) | SU1757462A3 (cs) |
| TN (1) | TNSN89103A1 (cs) |
| YU (1) | YU170189A (cs) |
| ZA (1) | ZA897212B (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE912760A1 (en) * | 1990-08-06 | 1992-02-12 | Smith Kline French Lab | Compounds |
| IE912759A1 (en) * | 1990-08-06 | 1992-02-12 | Smith Kline French Lab | Compounds |
| ZA911813B (en) * | 1990-08-09 | 1991-12-24 | Sankyo Co | (benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma |
| GB9113031D0 (en) * | 1991-06-17 | 1991-08-07 | Smithkline Beecham Plc | Compounds |
| US5578639A (en) * | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| US6201124B1 (en) | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
| US6153754A (en) * | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
| US5747523A (en) * | 1996-01-24 | 1998-05-05 | Guilford Pharmaceuticals Inc. | Substituted ethyl α,α-diarylmethyl ether derivatives |
| US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
| US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
| JP4932994B2 (ja) * | 1999-04-07 | 2012-05-16 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | 抗癌性カルシウムチャンネル遮断薬 |
| JP2006512278A (ja) * | 2001-06-13 | 2006-04-13 | テバ ファーマシューティカル インダストリーズ リミティド | アルコキシ不純物を実質的に含有しないパロキセチンの製造方法 |
| JP6017964B2 (ja) | 2010-03-01 | 2016-11-02 | ティーエーユー・セラピューティクス・エルエルシー | 癌診断および撮像 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1545094A (en) * | 1976-12-14 | 1979-05-02 | Gist Brocades Nv | Piperazine derivatives |
-
1988
- 1988-09-23 FR FR8812430A patent/FR2636946B1/fr not_active Expired - Lifetime
-
1989
- 1989-09-06 YU YU01701/89A patent/YU170189A/xx unknown
- 1989-09-19 DE DE68912860T patent/DE68912860T2/de not_active Expired - Fee Related
- 1989-09-19 IL IL91689A patent/IL91689A0/xx not_active IP Right Cessation
- 1989-09-19 AT AT89402561T patent/ATE101132T1/de not_active IP Right Cessation
- 1989-09-19 ES ES89402561T patent/ES2062071T3/es not_active Expired - Lifetime
- 1989-09-19 EP EP89402561A patent/EP0360685B1/fr not_active Expired - Lifetime
- 1989-09-20 JP JP1242360A patent/JPH02121964A/ja active Pending
- 1989-09-20 AR AR89314972A patent/AR246255A1/es active
- 1989-09-20 MA MA21885A patent/MA21631A1/fr unknown
- 1989-09-21 ZA ZA897212A patent/ZA897212B/xx unknown
- 1989-09-22 CA CA000612673A patent/CA1327364C/fr not_active Expired - Fee Related
- 1989-09-22 DK DK468389A patent/DK468389A/da not_active Application Discontinuation
- 1989-09-22 TN TNTNSN89103A patent/TNSN89103A1/fr unknown
- 1989-09-22 DD DD89332899A patent/DD284875A5/de not_active IP Right Cessation
- 1989-09-22 HU HU894981A patent/HU208422B/hu not_active IP Right Cessation
- 1989-09-22 SU SU894742008A patent/SU1757462A3/ru active
- 1989-09-22 NO NO89893764A patent/NO893764L/no unknown
- 1989-09-22 PT PT91783A patent/PT91783B/pt not_active IP Right Cessation
- 1989-09-22 AU AU41690/89A patent/AU617530B2/en not_active Ceased
- 1989-09-22 IE IE305089A patent/IE63648B1/en not_active IP Right Cessation
- 1989-09-22 NZ NZ230744A patent/NZ230744A/en unknown
- 1989-09-22 OA OA59651A patent/OA09135A/xx unknown
- 1989-09-22 US US07/410,705 patent/US4957927A/en not_active Expired - Fee Related
- 1989-09-22 CZ CS895409A patent/CZ279282B6/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA21631A1 (fr) | 1990-04-01 |
| YU170189A (en) | 1991-02-28 |
| TNSN89103A1 (fr) | 1991-02-04 |
| CA1327364C (fr) | 1994-03-01 |
| OA09135A (fr) | 1991-10-31 |
| AR246255A1 (es) | 1994-07-29 |
| FR2636946B1 (fr) | 1990-11-02 |
| NZ230744A (en) | 1991-06-25 |
| FR2636946A1 (fr) | 1990-03-30 |
| US4957927A (en) | 1990-09-18 |
| HUT52049A (en) | 1990-06-28 |
| EP0360685A1 (fr) | 1990-03-28 |
| ATE101132T1 (de) | 1994-02-15 |
| JPH02121964A (ja) | 1990-05-09 |
| PT91783A (pt) | 1990-03-30 |
| HU208422B (en) | 1993-10-28 |
| ES2062071T3 (es) | 1994-12-16 |
| DK468389D0 (da) | 1989-09-22 |
| AU4169089A (en) | 1990-03-29 |
| IE893050L (en) | 1990-03-23 |
| ZA897212B (en) | 1991-03-27 |
| CZ540989A3 (en) | 1994-11-16 |
| IL91689A0 (en) | 1990-06-10 |
| DK468389A (da) | 1990-03-24 |
| AU617530B2 (en) | 1991-11-28 |
| DE68912860D1 (de) | 1994-03-17 |
| CZ279282B6 (cs) | 1995-04-12 |
| IE63648B1 (en) | 1995-05-31 |
| NO893764D0 (no) | 1989-09-22 |
| EP0360685B1 (fr) | 1994-02-02 |
| SU1757462A3 (ru) | 1992-08-23 |
| PT91783B (pt) | 1995-08-09 |
| DE68912860T2 (de) | 1994-08-11 |
| NO893764L (no) | 1990-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69103206T2 (de) | Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel. | |
| DE3787688T2 (de) | Diamin-Verbindungen. | |
| DE3248160C2 (de) | 2-[4-[(4,4-Dialkyl-2,6-piperidindion-1-yl)-butyl]-1-piperazinyl]pyrimidine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten | |
| DE2203373C3 (de) | Neue 2- [(2- Alkylbenzofuran-3-yl)-methyl] -A2 -imidazoline | |
| DE69116705T2 (de) | Antiglancoma-Zusammensetzungen enthaltend 3-Arylcarbonyl-1-aminoalkyl-1H-indol | |
| DE602005005456T2 (de) | Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen | |
| EP0136658A2 (de) | 1-Benzyl-aminoalkyl-pyrrolidinone und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE69120899T2 (de) | Neue N-Benzoylprolin-Derivate, Verfahren zur Herstellung und diese enthaltende Arzneimittel | |
| DE69004973T2 (de) | Piperidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel. | |
| DD284875A5 (de) | Verfahren zur herstellung von 1-[(diarylmethoxy)-alkyl]-pyrrolidinen und -piperidinen | |
| DE2363052C2 (cs) | ||
| DE2724989A1 (de) | Guanidinderivate, verfahren zu ihrer herstellung und arzneimittel | |
| CH637130A5 (de) | Chinazolin-derivate, verfahren zu ihrer herstellung und verwendung dieser derivate in arzneimitteln. | |
| DE69112074T2 (de) | Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen. | |
| DE2918523A1 (de) | Lactam-n-essigsaeuren und deren amide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| CH675418A5 (cs) | ||
| DD149071A5 (de) | Herstellung 2-substituierter trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole | |
| DE68911699T2 (de) | Diamin-Verbindungen. | |
| DE69116237T2 (de) | Derivate von Hexahydroazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE3856501T2 (de) | Schlafverbesserungsmittel | |
| DE2329430A1 (de) | 1-acyl-3-(amino-niedrig-alkyl)-indole | |
| DE69201368T2 (de) | 1-(Alkoxybenzyl)piperazineamide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
| EP0243905B1 (de) | 1(omega-[bis-(Phenyl)-alkoxy]-alkyl)-4-(di-(phenyl)-methyl)- Piperazine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE2044172A1 (de) | Neue Pyrroldenvate, ein Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittelzubereitungen | |
| DE3900028A1 (de) | Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |